Edison Investment Research - AdAlta (1AD) AdAlta - Moving to an inhaled formulation

Report

Edison Investment Research

Sean Conroy

AdAlta - Moving to an inhaled formulation

AdAlta has announced it will be moving forward with an inhaled formulation of AD-214 into efficacy studies in patients with idiopathic pulmonary fibrosis (IPF) rather than the original intravenous (IV) formulation. Preclinical studies with a radiolabelled version of AD-214 have indicated that IV dosing leads to much of the administered drug being rapidly distributed through the liver and cleared, rendering it unavailable to deliver a therapeutic effect. The company believes the advantages of an inhaled formulation will include a more direct form of administrations for lung diseases, potentially lower drug doses required for efficacy, and lower costs to manufacture and administer.

22/07/2021 1 EN

Underlying

AdAlta

Adalta develops its novel i-body platform with a focus on its candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

See profile

AU0000001AD2 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

AdAlta - Termination of coverage

Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

December 8, 2021 December 8, 2021 1 EN

Edison Investment Research

AdAlta - Termination of coverage

December 8, 2021 December 8, 2021 1 EN

Edison Investment Research

AdAlta - Moving into CAR-T

AdAlta has announced a collaboration with Carina Biotech, a private Australian company, in which the two companies will work together to develop chimeric antigen receptor T cell (CAR-T) therapies for solid tumours. Under the agreement, AdAlta will discover and optimise proprietary i-bodies on up to five undisclosed tumour antigen targets, from which Carina will generate bi-specific CAR-T cells and identify optimal candidates. We believe the CAR-Ts will be autologous, generated from a patient’s own cells. The two companies will jointly fund pre-clinical proof of concept studies in mouse tumour ...

August 31, 2021 August 31, 2021 1 EN

Nabaltec - Resilience and margin expansion

Nabaltec recorded revenue growth across the group of 1.5% y-o-y to €158.2m at 9M24, with sales volumes increasing 7.9% y-o-y despite selling prices falling. Functional Fillers revenue grew by 3.8% y-o-y to €114.1m due to strong demand for its viscosity optimised and fine precipitated aluminium hydroxides. Speciality Alumina revenue, however, decreased 4.1% y-o-y, partially offsetting group revenue growth due to a lack of impetus for reactive alumina in the wider market. Group EBIT grew 28.2% y-o-y to €16.8m (10.3% margin), due to higher capacity utilisation and lower costs of materials, energy...

13h / 7m 13h / 7m 1 EN

Kate Heseltine

Kate Heseltine

The Platform Group - Significant acceleration in growth in Q324

The Platform Group (TPG) reported a strong acceleration in revenue growth and profitability in Q324 as its growing industry presence and subsequent underlying growth provided an increase in most KPIs during the period. Its valuation continues to look attractive versus its online peers if management delivers on its expected growth rates.

15h / 23m 15h / 23m 1 EN

Toby Thorrington

Toby Thorrington

Theon International - Clear vision for growth

Theon International commands a unique position in military night vision systems as a market-leading business focused on man-portable systems (goggles). It has a market-leading position in Europe, an expanding presence globally and is developing adjacent product portfolios, most notably platforms like military vehicle vision systems. Its potential is supported by an addressable market of more than €3bn forecast to grow at double-digit rates. Combining this with a low capital-intensity business model should drive positive financials and strong cash generation.

17h / 7m 17h / 7m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

AdAlta - Moving to an inhaled formulation

AdAlta - Termination of coverage

AdAlta - Termination of coverage

AdAlta - Moving into CAR-T

Nabaltec - Resilience and margin expansion

The Platform Group - Significant acceleration in growth in Q324

Theon International - Clear vision for growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe